Alembic Pharmaceuticals Ltd share price logo

Alembic Pharmaceuticals Ltd

NSE: APLLTD

BSE: 533573

Small Cap

Pharma Sector

₹818.20

+8.80

(+1.09%)

as on

bell
The current prices are delayed by 15 mins, login to check live prices.

Tech Chart

🔔 Growth Outlook Alert

Alembic Pharma raises FY27 US growth outlook after strong Q1, driven by new product launches and exclusivity for Bosutinib; ICICI Securities upgrades target price.

Alembic Pharmaceuticals Stock Performance

as on August 5, 2026 at 9:31 pm IST

  • Day's Low

    Day's High

    ₹803.20
    ₹840.40
    downward going graph

    1.83%

    Downside

    2.71%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    ₹635.80
    ₹1,002.00
    downward going graph

    22.29%

    Downside

    22.46%

    Upside

    downward going graph

Alembic Pharmaceuticals share price movements today

Previous Close
₹809.40
Open
₹822.00
Volume
2.44L
Upper Circuit
₹971.25
Lower Circuit
₹647.55
Day's Low - High
₹803.20 - ₹840.40
52 Week Low - High
₹635.80 - ₹1,002.00

Alembic Pharmaceuticals Historical Returns

1 Month Return
-3.14 %
3 Month Return
+ 5.21 %
1 Year Return
-14.48 %
3 Year Return
+ 2.03 %
5 Year Return
+ 3.31 %

Alembic Pharmaceuticals Fundamentals

as on August 5, 2026 at 4:01 pm IST

Market Cap

₹15,909.82 Cr

Return on Equity (ROE)

12.9

PE Ratio (TTM)

22.95

Return on capital employed (ROCE)

12.01

Industry PE ratio

52.25

Beta (LTM)

0.93

P/B Ratio

2.32

Dividend Yield

1.81

PEG Ratio

4.95

Quarterly Earnings Growth YOY

12.19

EPS (TTM)

34.13

Book Value

288.72

Alembic Pharmaceuticals Stock Valuation

as on August 5, 2026 at 4:01 pm IST

Alembic Pharmaceuticals in the last 5 years

  • Overview

  • Trends

Lowest (11.53x)

March 23, 2020

Today (22.95x)

August 4, 2026

Industry (52.25x)

August 4, 2026

Highest (53.41x)

January 3, 2023

LowHigh

Today’s Price to Earnings Ratio: 22.95x

Alembic Pharmaceuticals Technical Analysis

Track how Alembic Pharmaceuticals technical analysis has moved over time to understand its trends.

1 min
5 min
15 min
30 min
1 day
1 week
1 month

Technicals Summary

Bearish

Neutral

Bullish

Bearish

Moving Averages

Bearish

Neutral

Bullish

Bearish

Oscillators

Bearish

Neutral

Bullish

Bearish

Overall

Bearish12
Bullish1
Neutral2

Oscillators

Name

Value

Action

MACD level (12,26)
-0.1
Bullish
CCI (20)
371.95
Bearish
RSI (14)
48.01
Neutral
Momentum (10)
1
Bearish
ADI (14)
20.14
Neutral
Ultimate Oscillator (7,14,28)
27.04
Bearish

Moving Averages

Name

Value

Action

SMA (20)
819.17
Bearish
EMA (20)
819.27
Bearish
VWMA (20)
819.16
Bearish
SMA (50)
819.63
Bearish
EMA (50)
820.05
Bearish
SMA (200)
825.15
Bearish
EMA (200)
823.36
Bearish
KAMA (200)
820.19
Bearish
DEMA (200)
822.34
Bearish

Alembic Pharmaceuticals Ltd vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Alembic Pharmaceuticals with its industry peers.

Company
Analyst View
Market Cap(in ₹ Cr)
5 Year CAGRDebt to Asset Ratio
Net Profit(in ₹ Cr)
Yearly Revenue(in ₹ Cr)
Alembic Pharmaceuticals Ltd image
Alembic Pharmaceuticals Ltd
HOLD15,909.820.66%0.626707,344
Sanofi India Ltd image
Sanofi India Ltd
BUY7,817.07-12.29%0.004132,013
Aurobindo Pharma Ltd image
Aurobindo Pharma Ltd
BUY92,109.3314.93%0.603,48331,723
Zydus Lifesciences Ltd image
Zydus Lifesciences Ltd
BUY1,12,717.9318.66%0.695,02651,180
Abbott India Ltd image
Abbott India Ltd
BUY59,128.1311.05%0.001,4146,445
See all

Market expectation of Alembic Pharmaceuticals Stock

Common consensus of the market based on various publicly available news, publications,brokerage expectation and market data

HOLD

44.44%

Buy

55.56%

Hold

0.00%

Sell

Alembic Pharmaceuticals Stock’s Investor Sentiment and Interest

Search interest for Alembic Pharmaceuticals Ltd Stock has decreased by -20% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-20% versus previous 30 day period

Alembic Pharmaceuticals Ltd Quarterly Profit & Loss

Figures in Rupees Crores

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Sales
1,594.93
1,630.57
1,516.98
1,561.73
1,647.98
1,692.74
1,769.64
1,710.72
1,910.15
1,876.31
1,847.72
2,149.77
Other Income
10.15
2.89
3.6
2.42
30.47
9.86
14.19
6.5
8.33
15.5
26.61
15.32
Total Income
1,605.08
1,633.46
1,520.58
1,564.15
1,678.45
1,702.6
1,783.83
1,717.22
1,918.48
1,891.81
1,874.33
2,165.09
Expenses
1,387.19
1,364.25
1,257.31
1,324.9
1,408.71
1,432.52
1,498.38
1,429.82
1,594.46
1,626.88
1,644.56
1,817.91
Operating Profit
207.74
266.32
259.67
236.83
239.27
260.22
271.26
280.9
315.69
249.43
203.16
331.86
Operating Profit Margin %
13.03%
16.33%
17.12%
15.16%
14.52%
15.37%
15.33%
16.42%
16.53%
13.29%
11%
15.44%
Profit Before Interest, Tax and Depreciation
217.89
269.21
263.27
239.25
269.74
270.08
285.45
287.4
324.02
264.93
229.77
347.18
Interest
15.69
15.17
10.94
13.18
18.81
22.26
24.52
23.52
24.23
23.31
22.56
27.61
Depreciation
67.56
69.45
69.48
69.04
70.51
70.04
68.99
73.77
76.07
80.12
88.59
97.71
Profit Before Tax
134.64
184.59
182.85
157.03
180.42
177.78
191.94
190.11
223.72
161.5
118.62
221.86
Tax Paid
-1.92
4.14
4.64
22.49
27.28
40.08
35.31
36.48
40.01
29.55
-82.91
49.5
Profit After Tax
136.56
180.45
178.21
134.54
153.14
137.7
156.63
153.63
183.71
131.95
201.53
172.36
Total Net profit including share of profit / Loss from associate company
136.56
180.45
178.21
134.54
153.14
137.7
156.63
153.63
183.71
131.95
201.53
172.36
EPS
6.95
9.23
9.07
6.84
7.79
7.01
7.98
7.85
9.4
6.76
10.31
8.8
Actual EPS
6.95
9.23
9.07
6.84
7.79
7.01
7.98
7.85
9.4
6.76
10.31
8.8
Adjusted EPS
6.95
9.23
9.07
6.84
7.79
7.01
7.98
7.85
9.4
6.76
10.31
8.8
Diluted EPS
6.95
9.23
9.07
6.84
7.79
7.01
7.98
7.85
9.4
6.76
10.31
8.8

Alembic Pharmaceuticals Ltd Annual Profit & Loss

Figures in Rupees Crores

Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
Sales
3,130.81
3,934.68
4,605.75
5,393.13
5,305.79
5,652.62
6,228.63
6,672.08
7,344.9
Other Income
7.03
9.38
40.36
87.29
55.74
2.74
28.31
56.29
54.66
Total Income
3,137.84
3,944.06
4,646.11
5,480.42
5,361.53
5,655.36
6,256.94
6,728.37
7,399.56
Expenses
2,487.72
3,061.1
3,461.8
3,912.85
4,431.63
4,975.17
5,296.25
5,663.84
6,293.43
Operating Profit
643.09
873.58
1,143.95
1,480.28
874.16
677.45
932.38
1,008.24
1,051.47
Operating Profit Margin %
20.54%
22.2%
24.84%
27.45%
16.48%
11.98%
14.97%
15.11%
14.32%
Profit Before Interest, Tax and Depreciation
650.12
882.96
1,184.31
1,567.57
929.9
680.19
960.69
1,064.53
1,106.13
Interest
3.4
18.41
27.16
16.02
17.73
50.17
56.19
78.77
93.63
Depreciation
105.46
115.23
157.32
183.47
286.78
275.43
272.67
278.58
318.55
Profit Before Tax
541.26
749.32
999.83
1,368.08
625.39
354.59
631.83
707.18
693.95
Tax Paid
120.35
156.75
199.18
253.32
104.45
12.6
16.01
125.17
23.12
Profit After Tax
420.91
592.57
800.65
1,114.76
520.94
341.99
615.82
582.01
670.83
Total Net profit including share of profit / Loss from associate company
412.82
583.29
800.7
1,146.5
520.94
341.99
615.82
582.01
670.83
EPS
21.89
31
43.97
60.81
26.5
17.4
31.33
29.68
34.33
Actual EPS
21.89
31
43.97
60.81
26.5
17.4
31.33
29.68
34.33
Adjusted EPS
21.89
31
43.97
60.81
26.5
17.4
31.33
29.68
34.33
Diluted EPS
21.89
31
43.97
60.81
26.5
17.4
31.33
29.68
34.33

Alembic Pharmaceuticals Ltd Cash Flow

Figures in Rupees Crores

Mar 2016
Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
Net Cash from Operating Activities
947.66
328.55
312.42
811.96
449.13
1,463.39
552.35
723.95
803.2
87.96
782.73
Cash Flow from Investing Activities
-5.7
-485.91
-884.38
-755.67
-731.22
-839.74
-371.97
-447.6
-320.61
-568.41
-506.06
Cash Flow from Financing Activities
-224.3
-128.88
502.63
59.04
154.86
-597.43
-217.35
-261.96
-437.86
443.72
-163.78
Net Cash Flow
416.55
-286.24
-69.33
115.33
-127.23
26.22
-36.97
14.39
44.73
-36.73
112.89

Alembic Pharmaceuticals Stock Shareholding Pattern

Numbers in percentages

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Promoters
69.61%
69.61%
69.61%
69.61%
69.61%
69.61%
69.67%
69.67%
69.74%
69.74%
69.74%
69.87%
DII
13.93%
14.5%
15.38%
15.47%
16.05%
16.06%
16.43%
16.46%
16.3%
16.17%
16.18%
15.94%
FII
0%
4.52%
4.46%
4.32%
3.94%
4.17%
3.94%
3.96%
4.05%
4.24%
4.25%
4.18%
Public
11.67%
11.37%
10.54%
10.6%
10.39%
10.16%
9.96%
9.9%
9.92%
9.85%
9.83%
10.01%
Total Outstanding Shares
19,65,63,124
19,65,63,124
19,65,63,124
19,65,63,124
19,65,63,124
19,65,63,124
19,65,63,124
19,65,63,124
19,65,63,124
19,65,63,124
19,65,63,124
19,65,63,124
Total Shareholders
89,552
85,212
76,567
74,829
91,429
93,944
91,336
89,013
89,969
87,000
86,432
86,796

Mutual Funds that own Alembic Pharmaceuticals Stock

Check out the Mutual Funds with significant holdings in Alembic Pharmaceuticals.

Alembic Pharmaceuticals Corporate Actions

View detailed summary of the earnings and dividend history of Alembic Pharmaceuticals.

  • Alembic Pharmaceuticals Ltd Earnings Results

    Alembic Pharmaceuticals Ltd’s net profit jumped 12.11% since last year same period to ₹173.07Cr in the Q1 2026-2027. On a quarterly growth basis, Alembic Pharmaceuticals Ltd has generated -14.62% fall in its net profits since last 3-months.

    Read More about Earnings Results

  • Alembic Pharmaceuticals Ltd Dividends May,2026

    In the quarter ending March 2026, Alembic Pharmaceuticals Ltd has declared dividend of ₹12.00 per share on 15 May 2026 - translating a dividend yield of 1.48%.

    Read More about Dividends

Indices Featuring Alembic Pharmaceuticals Stock

Check stock indices that include Alembic Pharmaceuticals.

BSE Healthcare

₹50,962.19

173.47 (▲0.34%)

Insights on Alembic Pharmaceuticals Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Promoter Holding Up

    img

    Promoters have increased holdings from 69.74% to 69.87% in Jun 2026 quarter

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 1.87K Cr → 2.16K Cr (in ₹), with an average increase of 13.4% per quarter

  • imgPOSITIVE IMPACT

    MF Holding Up

    img

    Mutual Funds have increased holdings from 8.18% to 8.73% in Jun 2026 quarter

  • imgPOSITIVE IMPACT

    Retail Holding Up

    img

    Retail Investor have increased holdings from 9.83% to 10.01% in Jun 2026 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Torrent Pharmaceuticals Ltd has given 40.1% return, outperforming this stock by 54.6%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Torrent Pharmaceuticals Ltd has given 145.2% return, outperforming this stock by 143.2%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, APLLTD stock has moved down by -0.3%

  • imgNEGATIVE IMPACT

    FII Holding Down

    img

    Foreign Institutions have decreased holdings from 4.25% to 4.18% in Jun 2026 quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, 202.7 Cr → 173.07 Cr (in ₹), with an average decrease of 14.6% per quarter

About Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals is a leading generic pharmaceuticals manufacturer and marketer based in India. Established in 2010 as a subsidiary of Alembic Ltd., they stopped being a subsidiary in 2011 when they were allotted 133515914 equity shares of Rs 2 each to their shareholders. In 2014 Alembic Pharmaceuticals entered into a joint venture with Adwiya Mami SARL, Algeria and in 2015 an exclusive agreement was signed with Novartis. In 2016, Alembic Pharmaceuticals formed Aleor Dermaceuitical Limited in a 60:40 joint venture with Orbicular and a state-of-the-art anticancer manufacturing facility opened in Gujarat in 2017. One year later Alembic Pharmaceuticals completed the acquisition of Orit Laboratories LLC, a generic drug developer, along with real estate. In 2018 Alembic Pharmaceuticals was inspected by the US FDA and were issued with 3 observations. In 2019, they launched 9 new products in the US, and the novel Umbralicib UKONIQ was licensed by TG Therapeutics USA in 2021. In 2022, Aleor Dermaceuticals was amalgamated into Alembic Pharmaceutical and became a wholly owned subsidiary.

Revenue: ₹2,149.77Cr as on June 2026 (Q1 FY27)
Net Profit: ₹172.36Cr as on June 2026 (Q1 FY27)
Listing date: 20 Sep, 2011
Chairperson Name: Chirayu R Amin
OrganisationAlembic Pharmaceuticals Ltd
HeadquartersVadodara
IndustryPharmaceuticals
CEOChirayu R Amin
E-voting on sharesClick here to vote

FAQs

What is Alembic Pharmaceuticals share price today?

Alembic Pharmaceuticals share price today stands at ₹818.2 as on at the close of the market. Alembic Pharmaceuticals share today touched a day high of ₹840.4 and a low of ₹803.2.

What is the 52 week high and 52 week low range for Alembic Pharmaceuticals share?

Alembic Pharmaceuticals touched a 52 week high of ₹1002 and a 52 week low of ₹635.8. Alembic Pharmaceuticals share price today i.e. is closed at ₹818.2, which is -18.34% down from its 52 week high and 28.69% up from its 52 week low.

What is Alembic Pharmaceuticals's market capitalisation today?

Alembic Pharmaceuticals market capitalisation is ₹15,909.82 Cr as on .

How to buy Alembic Pharmaceuticals shares?

To buy Alembic Pharmaceuticals shares, you need to follow these steps:

  • Open a Demat account and Trading account on INDmoney
  • Fund your Trading account
  • Search for APLLTD or Alembic Pharmaceuticals Ltd on the INDmoney app to check live prices of the stock
  • Click on Buy or SIP to place an order to invest in Alembic Pharmaceuticals shares. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.

What is Alembic Pharmaceuticals trading volume today?

Alembic Pharmaceuticals trading volume is 2.44L as on . This means that 2.44L shares of Alembic Pharmaceuticals were bought and sold on the stock market during today's trading session.